BURLINGTON, Mass., April 24, 2017 /PRNewswire/ -- Decision Resources Group finds that over the next ten years, the launches of novel selective progesterone receptor modulators (SPRMs)—Allergan/Gedeon Richter's ulipristal, Bayer's vilaprisan, and Repros's Proellex, and gonadotropin-releasing hormone (Gn-RH) antagonists—AbbVie's elagolix, Myovant's relugolix and ObsEva's OBE-2109, will provide efficacious medical alternatives to surgical procedures, such as hysterectomy and myomectomy, for the long-term management of uterine fibroids.

Other key findings from the Niche & Rare Disease Landscape & Forecast report entitled Uterine Fibroids (US/EU5):

  • DRG epidemiological analysis identifies a large number of prevalent cases of uterine fibroids among women aged 20-54 across the countries under study; however, the total prevalence of uterine fibroids is highest in Italy.
  • A great proportion of patients have been diagnosed with asymptomatic uterine fibroids and are typically monitored by gynecologists for growth in tumor size and number. According to the interviewed experts, magnetic resonance imaging is the gold standard diagnostic tool to determine localization, size, and structure of uterine fibroids, owing to its high sensitivity.
  • While low-cost hormonal contraceptives, tranexamic acid, and NSAIDs will remain the first-line drug therapies for controlling heavy menstrual bleeding associated with uterine fibroids, the number of procedures conducted will gradually decrease due to the availability of more-effective and safer second- and/or third-line pharmacological options for the long-term management of uterine fibroids.
  • Similarly, we forecast that drug treatment rate will gradually increase with the expansion of pharmacological treatment options for the long-term management of uterine fibroids.
  • Interviewed uterine fibroids experts are eager for the launch of SPRMs, particularly ulipristal, for the treatment of symptomatic uterine fibroids, but note concern over endometrial hyperplasia and the need for long-term safety data.
  • While the second-generation Gn-RH antagonists are expected to offer significant improvements over first-generation in-class drugs and Gn-RH agonists, novel SPRMs are expected to constrain the uptake of emerging Gn-RH antagonists in our analysis.

Comments from Decision Resources Group Analyst Jing Wu, M.S., M.B.A.:

  • "Medical alternatives, for instance, SPRMs and the second-generation, orally administered Gn-RH antagonists, which effectively control heavy menstrual bleeding and can bypass the need for surgical procedure, will be preferred by patients who opt to stay on drug therapy until menopause. The adoption of these novel therapies will be key in driving significant expansion of the uterine fibroids therapeutic market within the 2016-2026 forecast period."
  • "First-to-market players within the emerging drug classes, for instance, ulipristal and elagolix, are expected to dominate their respective niches in the treatment of uterine fibroids, while follow-on in-class competitors will struggle to gain market share if not sufficiently differentiated."

Learn more about our Uterine Fibroids disease offerings. 

About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.

Media contact:

Decision Resources Group
Whitney Goldstein
617-747-9037
wgoldstein@dresources.com

SOURCE Decision Resources Group

Unmet Need and Opportunity Assessment in Recurrent or Metastatic SCCHN: Are Immune Checkpoint Inhibitors the Answer?

View Now